stoxline Quote Chart Rank Option Currency Glossary
  
Absci Corporation (ABSI)
3.12  0.24 (8.33%)    07-18 16:00
Open: 2.9
High: 3.225
Volume: 8,665,446
  
Pre. Close: 2.88
Low: 2.895
Market Cap: 398(M)
Technical analysis
2025-07-18 4:38:54 PM
Short term     
Mid term     
Targets 6-month :  3.76 1-year :  4.39
Resists First :  3.22 Second :  3.76
Pivot price 2.71
Supports First :  2.77 Second :  2.49
MAs MA(5) :  2.79 MA(20) :  2.72
MA(100) :  2.89 MA(250) :  3.45
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  78.1 D(3) :  57.5
RSI RSI(14): 63.8
52-week High :  6.32 Low :  2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ABSI ] has closed above the upper band by 21.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 42.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 54 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.23 - 3.24 3.24 - 3.26
Low: 2.87 - 2.88 2.88 - 2.89
Close: 3.1 - 3.12 3.12 - 3.14
Company Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Headline News

Wed, 16 Jul 2025
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $7 to $13 - 富途牛牛

Mon, 14 Jul 2025
Absci Corporation (NASDAQ:ABSI) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Fri, 11 Jul 2025
Why Absci's AI-Driven Biotech Play Could Be the Next Breakout - AInvest

Fri, 11 Jul 2025
Morgan Stanley Assumes Coverage on Absci Corporation (ABSI) with $7 Target - Insider Monkey

Mon, 07 Jul 2025
Absci Appoints Biopharma Leader Mary Szela to Board of Directors - GlobeNewswire

Fri, 23 May 2025
Absci Corporation's (NASDAQ:ABSI) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures - simplywall.st

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 128 (M)
Held by Insiders 1.1025e+008 (%)
Held by Institutions 10.8 (%)
Shares Short 22,920 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -9.867e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 351.9 %
Return on Equity (ttm) -27.6 %
Qtrly Rev. Growth 4.82e+006 %
Gross Profit (p.s.) 15.12
Sales Per Share -23.66
EBITDA (p.s.) -2.98406e+007
Qtrly Earnings Growth -1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -76 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.14
Price to Cash Flow 4.13
Stock Dividends
Dividend 0
Forward Dividend 2.61e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android